# US 2011/0257182 A1 · Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257182 A1
- Document ID: US20110257182A1
- Status: Published application
- Kind: A1
- Application number: 13/135,069
- Filed: 2011-06-25
- Published: 2011-10-20
- Earliest claimed: 2007-07-13
- Inventors: Christelle Bolea
- Web page: https://patentgrep.com/patent/US20110257182A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A23L 27/20: Synthetic spices, flavouring agents or condiments
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 213/79: Acids; Esters
- C07D 213/81: Amides; Imides
- C07D 239/28: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 333/40: Thiophene-2-carboxylic acid
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel compounds of Formula (I), wherein X1, X2, X3, X4, Am and Bn are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

## Claims

### Claim 1

A compound having the Formula (I-b),
a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an N-oxide form thereof, wherein:
X1 is N and X2, X3 and X4 are each independently selected from the group of C, N, O, S and C═C representing a 5 or 6 membered heteroaryl ring which may further be substituted by 1 to 3 radicals Am;
m is an integer ranging from 1 to 3;
Am radicals are each independently selected from the group of hydrogen, halogen, —CN, —OH, —NO2, —CF3, —SH, —NH2 and an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)alkylhalo, —(C3-C7)cycloalkyl, —(C1-C6)alkylcyano, —(C1-C6)alkylheteroaryl, —(C1-C6)alkylaryl, aryl, heteroaryl, heterocycle, —(C0-C6)alkyl-OR1, —O—(C2-C6)alkyl-OR1, —NR1(C2-C6)alkyl-OR2, —(C3-C7)cycloalkyl-(C1-C6)alkyl, —O—(C3-C7)cycloalkyl-(C1-C6)alkyl, —NR1—(C3-C7)cycloalkyl-(C1-C6)alkyl, —(C1-C6)alkylhalo-OR1, —(C1-C6)alkylhalo-NR1R2, —(C0-C6)alkyl-S—R1, —O—(C2-C6)alkyl-S—R1, —NR1—(C2-C6)alkyl-S—R2, —(C0-C6)alkyl-S(═O)—R1, —O—(C1-C6)alkyl-S(═O)—R1, —NR1—(C1-C6)alkyl-S(═O)—R2, —(C0-C6)alkyl-S(═O)2—R1, —O—(C1-C6)alkyl-S(═O)2—R1, —NR1—(C1-C6)alkyl-S(═O)2—R2, —(C0-C6)alkyl-NR1R2, —O—(C2-C6)alkyl-NR1R2, —NR1—(C2-C6)alkyl-NR2R3—(C0-C6)alkyl-S(═O)2NR1R2, —O—(C1-C6)alkyl-S(═O)2NR1R2, —NR1—(C1-C6)alkyl-S(═O)2NR2R3, —(C0-C6)alkyl-NR1—S(═O)2R2, —O—(C2-C6)alkyl-NR1—S(═O)2R2, —NR1—(C2-C6)alkyl-NR2—S(═O)2R3, —(C0-C6)alkyl-C(═O)—NR1R2, —O—(C1-C6)alkyl-C(═O)—NR1R2, —NR1—(C1-C6)alkyl-C(═O)—NR2R3, —(C0-C6)alkyl-NR1C(═O)—R2, —O—(C2-C6)alkyl-NR1C(═O)—R2, —NR1—(C2-C6)alkyl-NR2C(═O)—R3, —(C0-C6)alkyl-OC(═O)—R1, —O—(C2-C6)alkyl-OC(═O)—R1, —NR1—(C2-C6)alkyl-OC(═O)—R2, —(C0-C6)alkyl-C(═O)—OR1, —O—(C1-C6)alkyl-C(═O)—OR1, —(C1-C6)alkyl-C(═O)—OR2, —(C0-C6)alkyl-C(═O)—R1, —O—(C1-C6)alkyl-C(═O)—R1, —NR1—(C1-C6)alkyl-C(═O)—R2, —(C0-C6)alkyl-NR1—C(═O)—OR2, —(C0-C6)alkyl-O—C(═O)—NR1R2, —(C0-C6)alkyl-NR1—C(═NR2)—NR3R4, —(C0-C6)alkyl-NR1—C(═O)—NR2R3, C6)alkyl-NR1—C(═O)—NR2R3, —NR1—(C2-C6)alkyl-NR2—C(═O)—NR3R4 and —(C0-C6)alkyl-NR1—C(═S)—NR2R3;
Any two radicals of Am (A1 and A2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R1, R2, R3 and R4 are each independently hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkylhalo, —(C1-C6)alkyl, —(C1-C6)alkylcyano, —(C3-C7)cycloalkyl, —(C4-C10)alkylcycloalkyl, heteroaryl, —(C1-C6)alkylheteroaryl, aryl, heterocycle and —(C1-C6)alkylaryl;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
B1 is selected from the group of hydrogen, halogen, —CN, —OH, —NO2, —CF3, —SH, —NH2 and an optionally substituted radical selected from the group of —(C1-C6)alkyl, —(C1-C6)alkylhalo, —(C3-C7)cycloalkyl, —(C1-C6)alkylcyano, —(C1-C6)alkylheteroaryl, —(C1-C6)alkylaryl, aryl, heteroaryl, heterocycle, —(C0-C6)alkyl-OR5, —O—(C2-C6)alkyl-OR5, —NR5(C2-C6)alkyl-OR6, —(C3-C7)cycloalkyl-(C1-C6)alkyl, —O—(C3-C7)cycloalkyl-(C1-C6)alkyl, —NR5—(C3-C7)cycloalkyl-(C1-C6)alkyl, —(C1-C6)alkylhalo-OR5, —(C1-C6)alkylhalo-NR5R6, —(C0-C6)alkyl-S—R5, —O—(C2-C6)alkyl-S—R5, —NR5—(C2-C6)alkyl-S—R6, —(C0-C6)alkyl-S(═O)—R5, —O—(C1-C6)alkyl-S(═O)—R5, —NR5—(C1-C6)alkyl-S(═O)—R6, —(C0-C6)alkyl-S(═O)2—R5, —O—(C1-C6)alkyl-S(═O)2—R5, —NR5—(C1-C6)alkyl-S(═O)2—R6, —(C0-C6)alkyl-NR5R6, —O—(C2-C6)alkyl-NR5R6, —NR5—(C2-C6)alkyl-NR6R7, —(C0-C6)alkyl-S(═O)2NR5R6, —O—(C1-C6)alkyl-S(═O)2NR5R6, —NR5—(C1-C6)alkyl-S(═O)2NR6R7, —(C0-C6)alkyl-NR5—S(═O)2R6, —O—(C2-C6)alkyl-NR5—S(═O)2R6, —NR5—(C2-C6)alkyl-NR6—S(═O)2R7, —(C0-C6)alkyl-C(═O)—NR5R6, —O—(C1-C6)alkyl-C(═O)—NR5R6, —NR5—(C1-C6)alkyl-C(═O)—NR6R7, —(C0-C6)alkyl-NR5C(═O)—R6, —O—(C2-C6)alkyl-NR5C(═O)—R6, —NR5—(C2-C6)alkyl-NR6C(═O)—R7, —(C0-C6)alkyl-OC(═O)—R5, —O—(C2-C6)alkyl-OC(═O)—R5, —NR5—(C2-C6)alkyl-OC(═O)—R6, —(C0-C6)alkyl-C(═O)—OR5, —O—(C1-C6)alkyl-C(═O)—OR5, —NR5—(C1-C6)alkyl-C(═O)—OR6, —(C0-C6)alkyl-C(═O)—R5, —O—(C1-C6)alkyl-C(═O)—R5, —NR5—(C1-C6)alkyl-C(═O)—R6, —(C0-C6)alkyl-NR5—C(═O)—OR6, —(C0-C6)alkyl-O—C(═O)—NR5R6, —(C0-C6)alkyl-NR5—C(═NR6)—NR7R8, —(C0-C6)alkyl-NR5—C(═O)—NR6R7, —O—(C2-C6)alkyl-NR5—C(═O)—NR6R7, —NR5—(C2-C6)alkyl-NR6—C(═O)—NR7R8 and —(C0-C6)alkyl-NR5—C(═S)—NR6R7;
B2 is an optionally substituted aryl or heteroaryl;
R5, R6, R7 and R8 are each independently hydrogen or an optionally substituted radical selected from the group of —(C1-C6)alkylhalo, —(C1-C6)alkyl, —(C1-C6)alkylcyano, —(C3-C7)cycloalkyl, —(C4-C10)alkylcycloalkyl, heteroaryl, —(C1-C6)alkylheteroaryl, aryl, heterocycle and —(C1-C6)alkylaryl;
Any two radicals of R (R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
provided that:
(i)
cannot be
and provided that:
(ii)
cannot be
and provided that:
(iii)
cannot be

### Claim 2 (depends on 1)

A compound according to claim 1, which can exist as optical isomers, wherein said compound is either the racemic mixture or one or both of the individual optical isomers.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein said compound is selected from:
N-(3,4-dichlorophenyl)-1H-pyrrole-2-carboxamide
N-(3-Chlorophenyl)-1H-imidazole-2-carboxamide
N-(3-Methoxyphenyl)thiophene-2-carboxamide
5-Methyl-N-(4-phenoxyphenyl)furan-2-carboxamide
Furan-2-carboxylic acid {3-[2-(4-fluoro-phenyl)-2-oxo-ethoxy]-phenyl}-amide
N-(3-Methoxyphenyl)picolinamide
N-(3-Methoxyphenyl)-2-methylthiazole-4-carboxamide
N-(3-Chlorophenyl)thiophene-2-carboxamide
5-Bromo-N-(3-methoxyphenyl)furan-2-carboxamide
N-(3-Chlorophenyl)picolinamide
N-(3-Methoxyphenyl)thiazole-2-carboxamide
N-(3-(2-(3-Methoxyphenyl)-2-oxoethoxy)phenyl)furan-2-carboxamide
N-(3-(2-Oxo-2-p-tolylethoxy)phenyl)furan-2-carboxamide
N-(3-(2-(4-Methoxyphenyl)-2-oxoethoxy)phenyl)furan-2-carboxamide
N-(3-(1-Oxo-1-p-tolylpropan-2-yloxy)phenyl)furan-2-carboxamide
N-(3-(Trifluoromethoxy)phenyl)picolinamide
N-(3-(2-(3-Chlorophenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3-(3-Phenylpropoxy)phenyl)picolinamide
N-(3-(2-(2-Methoxyphenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3-(2-(3-Methoxyphenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3-(2-(3-Fluorophenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3-(2-(2-Chlorophenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3-Fluorophenyl)picolinamide
N-(3-Methoxyphenyl)-5-methylisoxazole-3-carboxamide
N-(4-Fluoro-3-methoxyphenyl)picolinamide
N-(3-Chlorophenyl)-1H-pyrrole-2-carboxamide
N-(3-(2-(2-Fluorophenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3-Methoxyphenyl)pyrimidine-4-carboxamide
6-Fluoro-N-(4-fluoro-3-methoxyphenyl)picolinamide
N-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)picolinamide
N-(4-Fluoro-3-methoxyphenyl)thiazole-2-carboxamide
and a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an N-oxide form thereof.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein said compound is selected from:
N-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)-2-methylthiazole-4-carboxamide
N-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)thiazole-2-carboxamide
N-(3-Chloro-4-morpholinophenyl)picolinamide
N-(3-Chloro-4-(pyridin-2-yloxy)phenyl)picolinamide
N-(3-Chloro-4-(2,5-difluorophenoxy)phenyl)picolinamide
N-(3-Chloro-4-(2-chlorophenoxy)phenyl)picolinamide
N-(3-Chloro-4-(5-(trifluoromethyl)pyridin-2-yloxy)phenyl)picolinamide
N-(3-Chloro-4-(4-isobutyrylpiperazin-1-yl)phenyl)picolinamide
N-(3-Methoxy-4-(pyrimidin-2-yloxy)phenyl)picolinamide
N-(4-(Trifluoromethoxy)phenyl)picolinamide
N-(3-Chloro-4-(3-chlorophenoxy)phenyl)picolinamide
N-(3-Chloro-4-(3-fluorophenoxy)phenyl)picolinamide
N-(3-Chloro-4-(4-fluorophenoxy)phenyl)picolinamide
N-(3-Chloro-4-(4-chlorophenoxy)phenyl)picolinamide
N-(3-Chloro-4-(4-propionylpiperazin-1-yl)phenyl)picolinamide
N-(4-(4-Benzoylpiperazin-1-yl)-3-chlorophenyl)picolinamide
N-(3-Chloro-4-(4-cyanophenoxy)phenyl)picolinamide
N-(3-Chloro-4-(3-cyanopyridin-2-yloxy)phenyl)picolinamide
N-(4-(4-Benzylpiperazin-1-yl)-3-chlorophenyl)picolinamide
and a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically
isomeric form thereof and an N-oxide form thereof.

### Claim 5 (depends on 1, 2, 3, 4)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claims 1 to 4 and a pharmaceutically acceptable carrier and/or excipient.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 allosteric modulators, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 5.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 positive allosteric modulators, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 5.

### Claim 8 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing central nervous system disorders selected from the group consisting of: addiction, tolerance or dependence, affective disorders, such as depression and anxiety, psychiatric disease such as psychotic disorders, attention-deficit/hyperactivity disorder and bipolar disorder; Parkinson's disease, memory impairment, Alzheimer's disease, dementia, delirium tremens, other forms of neurodegeneration, neurotoxicity, and ischemia, comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 5.

### Claim 9 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing central nervous system disorders selected from the group consisting of Parkinson's disease and movement disorders such as bradykinesia, rigidity, dystonia, drug-induced parkinsonism, dyskinesia, tardive dyskinesia, L-DOPA-induced dyskinesia, dopamine agonist-induced dyskinesia, hyperkinetic movement disorders, Gilles de la Tourette syndrome, resting tremor, action tremor, akinesia, akinetic-rigid syndrome, akathisia, athetosis, asterixis, tics, postural instability, postencephalitic parkinsonism, muscle rigidity, chorea and choreaform movements, spasticity, myoclonus, hemiballismus, progressive supranuclear palsy, restless legs syndrome, periodic limb movement disorder, comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 5.

### Claim 10 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing central nervous system disorders selected from the group consisting of cognitive disorders: delirium, substance-induced persisting delirium, dementia, dementia due to HIV disease, dementia due to Huntington's disease, dementia due to Parkinson's disease, Parkinsonian-ALS demential complex, dementia of the Alzheimer's type, substance-induced persisting dementia and mild cognitive impairment comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 5.

### Claim 11 (depends on 1, 2, 3, 4, 5)

A method useful for treating affective disorders, anxiety, Agoraphobia, Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Phobia, Other Phobias, Substance-Induced Anxiety Disorder, acute stress disorder comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 5.

### Claim 12 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing central nervous system disorders selected from the group consisting of mood disorders: Bipolar Disorders (I & II), Cyclothymic Disorder, Depression, Dysthymic Disorder, Major Depressive Disorder, Substance-Induced Mood Disorder, comprising administering an effective amount of a compound/composition according to claims 1 to 5.

### Claim 13 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing neurological disorders selected from the group of neurodegeneration, neurotoxicity or ischemia such as stroke, spinal cord injury, cerebral hypoxia, intracranial hematoma, Parkinson's disease, memory impairment, Alzheimer's disease, dementia, delirium tremens comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 5.

### Claim 14 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing inflammatory central nervous system disorders selected from multiple sclerosis forms such as benign multiple sclerosis, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, progressive-relapsing multiple sclerosis, comprising administering an effective amount of a compound/composition according to claims 1 to 5.

### Claim 15 (depends on 1, 2, 3, 4, 5)

A method useful for treating migraine comprising administering an effective amount of a compound/composition according to claims 1 to 5.

### Claim 16 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing epilepsy and tremor, temporal lobe epilepsy, epilepsy secondary to another disease or injury e.g., chronic encephalitis, traumatic brain injury, stroke or ischemia comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 5.

### Claim 17 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing inflammation and/or neurodegeneration resulting from traumatic brain injury, stroke, ischemia, spinal cord injury, cerebral hypoxia or intracranial hematoma, comprising administering to a mammal in need of such treatment an effective amount of a compound/composition according to claims 1 to 5.

### Claim 18 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing sensory, motor or cognitive symptoms resulting from traumatic brain injury, stroke, ischemia, spinal cord injury, cerebral hypoxia or intracranial hematoma, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 5.

### Claim 19 (depends on 1, 2, 3, 4, 5)

A method useful for treating medulloblastomas comprising administering an effective amount of a compound/composition according to claims 1 to 5.

### Claim 20 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing inflammatory or neuropathic pain comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 5.

### Claim 21 (depends on 1, 2, 3, 4, 5)

A method useful for treating, or preventing, ameliorating, controlling or reducing the risk of various metabolic disorders associated with glutamate dysfunction comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 5.

### Claim 22 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing type 2 diabetes comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 5.

### Claim 23 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing diseases or disorders of the retina, retinal degeneration or macular degeneration, comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 5.

### Claim 24 (depends on 1, 2, 3, 4, 5)

A method useful for treating or preventing diseases or disorders of the gastrointestinal tract including gastro-esophageal reflux disease (GERD), lower esophageal sphincter diseases or disorders, diseases of gastrointestinal motility, colitis, Crohn's disease or irritable bowel syndrome (IBS), comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 5.

### Claim 25 (depends on 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of a compound according to claims 1 to 4 in the manufacture of a medicament for a treatment or prevention as defined in any of claims 6 to 24.

### Claim 26 (depends on 1, 2, 3, 4)

Use of a compound according to claims 1 to 4 to prepare a tracer for imaging a metabotropic glutamate receptor.

### Claim 27 (depends on 1, 2, 3, 4)

Use of a compound according to claims 1 to 4 as a taste agent, flavour agent, flavour enhancing agent or a food or beverage additive.
